



Aurobindo Pharma receives four new registrations from MCC – South Africa

Aurobindo Pharma Ltd is pleased to announce that it has received registrations from the Medicines Control Council (MCC) to manufacture and market 4 products under the CNS (Central Nervous System) segment, in South Africa.

#	Product Name	Dosage Form	Active Ingredient	Category
1	AUROPIDONE 1mg, 2mg, 3mg and 4mg	Tab	Risperidone 1mg	CNS
2	AUROPIDONE 1mg/ml	Solution	Risperidone 1mg/ml	CNS
3	AURO -RISPERIDONE 1mg/ml (Duplicate Dossier)	Solution	Risperidone 1mg/ml	CNS
4	AURO-SUMATRIPAN 50mg and 100 mg	Tab	Sumatripan 50mg	CNS

Aurobindo now has a total of 38 registrations approved by the MCC.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com